Page 1

September 23 , 2021 poxel Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update • Strengthened financial position with the approval of TWYMEEGⓇ ( Imeglimin hydrochloride ) for the treatment of type 2 diabetes in Japan : • Allowed Poxel to draw the third and final tranche of the IPF loan for EUR 13.5 million - included in the Q2 cash and cash equivalents of EUR 36.9 million 。 Triggered a milestone payment of JPY 1.75 billion ( approximately EUR 13.2 million , USD 15.8 million ) 1 from Sumitomo Dainippon Pharma to Poxel which was paid in July 2021 ( not included in Q2 cash and cash equivalents ) • Increasing strategic focus on rare metabolic diseases with continued commitment to non - alcoholic steatohepatitis ( NASH ) : 。 Patient enrollment in PXL065 DESTINY Phase 2 trial in NASH was completed in September 2021 with results expected in Q3 2022 。 Phase 2a clinical Proof of Concept ( POC ) biomarker studies of PXL065 and PXL770 in X - linked adrenoleukodystrophy ( ALD ) planned to initiate in early 2022 with data expected by year end 2022 • Webcast on Thursday , September 23 , at 12:00 pm ET / 6:00 pm CEST ( in French ) , 1:00 pm ET / 7:00 pm CEST ( in English ) LYON , France -- ( BUSINESS WIRE ) -- POXEL SA ( Euronext – POXEL - FR0012432516 ) , a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology , including non - alcoholic steatohepatitis ( NASH ) and rare disorders , today announced its financial results for the period ended June 30 , 2021 and provided a corporate update . " Thus far , 2021 has proven to be a pivotal year for Poxel as exemplified by the approval and subsequent product launch of TWYMEEGⓇ in Japan . This first product approval highlights our proven capabilities to deliver upon our corporate and clinical goals and to bring improved metabolic therapeutics to patients . This achievement has strengthened our near - term financial position and will continue to enhance our financial foundation with associated future royalties and sales - based payments , " said Thomas Kuhn , CEO of Poxel . " We also look forward to harnessing the full potential of our strategic shift with an increased focus on rare metabolic diseases , in addition to our ongoing commitment to NASH . Poxel is well- positioned to leverage its existing platforms to develop therapeutics in rare metabolic diseases , " Mr. Kuhn concluded .